IOL Chemicals and Pharmaceuticals Limited board has approved top management changes with effect from April 3, 2023 for the smooth functioning of the company.

Vikas Gupta has been promoted from Executive Director to Joint Managing Director of the company. Abhiraj Gupta has been promoted as Additional Director in the category of Executive Director and Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company.

Vikas Gupta graduated from King’s College London, University of London, with a Bachelor of Science in Business Management. Over the last 10 years, he has been critical to the organization’s operations, marketing, and strategy where he was instrumental in developing the company’s businesses. Vikas plays a significant role in guiding the company’s chemical and pharmaceutical business.

Abhiraj Gupta, Bachelor of Science in Management and Engineering in Business Management from University of Warwick, UK has been associated with the company since September 2017. He possesses the requisite qualifications and experience related to the business of the company and presently he is responsible for non-ibuprofen API and chemical business, R&D, regulatory and digital marketing of the company. Under his leadership the non-ibuprofen API business is performing well.

Vikas Vij has joined IOL as its ’Chief Executive Officer. Vikas has had a dynamic career spanning over 30 years reflecting pioneering experience and year-on-year success in achieving revenue, profitability and business growth objectives in start-up and established organizations.

Vikas has a Techno-commercial background with deep understanding of API and Chemical Industry and operations across Manufacturing, R&D, Procurement, SCM, RA & QA. He has a comprehensive knowledge of critical business drivers in both advanced and emerging markets.

He has handled various leadership roles across Pharma value chain such as Active Pharmaceutical Ingredients (APIs), Finished Dosage Form (FDF), Custom Pharmaceutical Services (CRAMS), Specialty Chemicals, and achieved multi- million dollar sales targets. He joins from Cipla where he was leading the API and Access Business Units. His earlier stints have been with Sun Pharma and Ranbaxy.